维基百科

胸苷激酶

胸苷激酶（英语：thymidine kinase）是一种磷酸转移酶（激酶）：2’-脱氧胸苷激酶，三磷酸腺苷-胸苷 5’-磷酸转移酶，EC 2.7.1.21[2][3]存在于大部分活体细胞中。它以两种同工酶的形式存在于哺乳动物细胞中，TK1和TK2。某些病毒同样含有病毒性胸苷激酶表达的遗传信息。

胸苷激酶
Crystal structure of a tetramer of thymidine kinase from U. urealyticum (where the monomers are color cyan, green, red, and magenta respectively) in complex with thymidine (space-filling model, carbon = white, oxygen = red, nitrogen = blue).[1]
识别码
EC编号 2.7.1.21
CAS号 9002-06-6
数据库
IntEnz IntEnz浏览
BRENDA（英语：BRENDA） BRENDA入口
ExPASy（英语：ExPASy） NiceZyme浏览
KEGG KEGG入口
MetaCyc（英语：MetaCyc） 代谢路径
PRIAM（英语：PRIAM_enzyme-specific_profiles） 概述
PDB RCSB PDB PDBj PDBe PDBsum
基因本体 AmiGO / EGO
胸苷激酶
鉴定
标志TK
PfamPF00265（旧版）
Pfam宗系CL0023（旧版）
InterPro（英语：InterPro）IPR001267
PROSITE（英语：PROSITE）PDOC00524
胸苷激酶1，可溶
识别
符号 TK1
Entrez 7083
HUGO 11830
OMIM 188300
RefSeq NM_003258
UniProt P04183
其他资料
EC编号 2.7.1.21
基因座 17 q23.2-25.3
胸苷激酶2，线粒体
识别
符号 TK2
Entrez 7084
HUGO 11831
OMIM 188250
RefSeq NM_004614
UniProt O00142
其他资料
EC编号 2.7.1.21
基因座 16 [1]

胸苷激酶催化以下反应：

•Thd + ATP → TMP + ADP

Thd是脱氧胸苷，ATP是5’-三磷酸-腺苷，TMP是5’-一磷酸-脱氧胸苷，ADP是5’-二磷酸-腺苷。

胸苷激酶的主要作用体现在细胞分裂过程中的DNA合成期，是介导脱氧胸苷进入DNA合成的旁路途经的一部分。脱氧胸苷存在于体液中，是食物细胞或机体细胞死亡后，DNA凋亡退化的产物。很多抗病毒药物的反应都需要胸苷激酶的参与。

胸苷激酶可用于在生产单克隆抗体过程中，筛选杂交瘤细胞。临床医学中，胸苷激酶作为一种细胞增殖标志物，用于恶性肿瘤的辅助诊断，治疗监控和跟踪随访。最近也有研究报道提出，胸苷激酶在早期癌症预防中的应用价值。

历史

胸苷参与DNA合成的途经是在1950年前后发现的[4]，后来进一步明确，这一途经始于胸苷的磷酸化[5]；在1960年左右，参与此过程的激酶（胸苷激酶）被首次纯化出来并进行了鉴定[6][7]。


分类

目前已得到鉴别的胸苷激酶可分为两大类[8][9]：

一类存在于疱疹病毒与细胞胸苷激酶类似；

一类广泛存在于脊椎动物，细菌，T4噬菌体，痘病毒，非洲猪瘟病毒（ASFV）和鱼淋巴囊肿病毒（FLDV）。昆虫虹彩病毒衣壳蛋白也属于此类。

目前只确认了细胞胸苷激酶的蛋白位点模型。

生化特点

高等生物胸苷激酶以两种同工酶形式存在，TK1和TK2，具有很大的化学差异性。

前一种最初在胎儿组织中发现，后一种大量存在于成人组织，所以最初，被分别命名为胎儿胸苷激酶和成人胸苷激酶。不久之后发现，TK1仅于细胞分裂初期（与细胞周期相关）存在于细胞质中[10][11]，而TK2定位于线粒体中，与细胞周期无关[12][13]。

1970年代中期定位了两种酶的基因[14][15]，TK1基因的克隆和测序完成[16]，其所对应蛋白的分子量为25kD；通常以二聚体的形式出现在组织中，能够被ATP激活；激活后，转化为四聚体。重组后的TK1无法被激活也无法转化为四聚体，表明这种存在于细胞中的激酶在合成后性状已经发生了改变[17][18][19]。

细胞中TK1的合成发生在细胞分裂周期的S期。细胞分裂完成后，TK1在细胞内部降解，因此在正常细胞分裂中，TK1一般不会进入体液[20]。细胞中胸苷激酶的反馈调节作用机理：三磷酸胸苷（TTP：胸苷磷酸化后的终产物）扮演着胸苷激酶抑制剂的角色[21][22][23][24]。这一机制确保了核酸合成所需的TTP量维持在平衡状态，而不会出现过饱和。5'-氨基胸苷是一种无毒性的胸苷类似物，能够干扰这一调控机理，因此，胸苷类似物作为一种细胞毒性物质被应用于很多抗肿瘤药物[25][26][27][28][29][30][31]。

一些病毒的特殊胸苷激酶基因也已经得到了鉴别，如单纯疱疹病毒，水痘带状疱疹病毒和EB病毒（一种疱疹病毒）[32][33][34][35][36][37][38]。

生理学背景

胸苷激酶催化反应的产物——一磷酸脱氧胸苷，会继续被胸苷酸激酶催化生成二磷酸脱氧胸苷，之后再被二磷酸核苷激酶催化生成三磷酸脱氧胸苷。在互补DNA和DNA聚合酶的催化作用下（或是逆转录过程中，在RNA和逆转录酶的作用下），三磷酸脱氧胸苷进入了DNA分子。

一磷酸脱氧胸苷可由两种不同的反应得到——一种是前文所述的脱氧胸苷磷酸化反应得到；还有一种是在不动用胸苷的情况下，通过胸苷酸磷酸酶催化其他代谢途径产生的脱氧尿苷甲基化反应得到。细胞在正常情况下（非细胞分裂状态）采用第二种途径为DNA修复提供充足的一磷酸脱氧胸苷。但当细胞准备分裂时，需要构建一组全新的DNA，对组成DNA的材料，如三磷酸脱氧胸苷的需求也增加了。在准备细胞分裂的过程中，一些细胞分裂所必需的酶开始产生。

这些酶平时不存在于细胞中，当细胞分裂完成后，在调控下浓度降低，最终降解。这一类酶被称为补救酶。胸苷激酶1（TK1）就是一种补救酶，但胸苷激酶2（TK2）却与细胞周期不相关[39][40][41][42][43][44][45][46][47]。

用途

鉴别处于分裂期的细胞

胸苷激酶在生化研究中的第一种直接应用是联合放射性标记的胸苷和后继用来测定放射活性的放射自显影技术来鉴别处于分裂期的细胞。为了达到此目的，氚化的胸苷需保存在培养基中。[48] 尽管技术上存在缺陷，该技术仍被用来测定恶性肿瘤细胞的增殖比例和研究免疫过程中淋巴细胞的活性。

PET 扫描活体肿瘤

3’-脱氧-3’-[氟18]氟化胸苷是一种胸苷类似物。它由胸苷激酶1调控，被迅速增殖的肿瘤组织优先摄取。同位素氟18是一种在正电子发射型断层显像技术（PET）中常用的正电子发射体。这种标记物和另一常用的标记物2-[氟18]氟基-2-脱氧-D-葡萄糖相比，在对增殖状态的活体肿瘤的PET成像方面更有优势[49][50][51][52][53]。

筛选杂交瘤细胞

杂交瘤细胞是肿瘤细胞（具有无限分裂能力）和B淋巴细胞融合后获得的。杂交瘤细胞能够持续、大量地产生具有专属特异性的免疫球蛋白（单克隆抗体）。但问题是如何在细胞融合后，从大量的多余的未融合细胞中，挑选出杂交瘤细胞。

一种解决该问题的方法就是使用胸苷激酶阴性（TK-）的肿瘤细胞系进行融合。在增殖的肿瘤细胞系中加入胸苷类似物，将杀死胸苷激酶阳性（TK+）细胞，如此就得到了胸苷激酶阴性细胞。然后，这些阴性细胞用来与胸苷激酶阳性的（TK+）B淋巴细胞进行融合。融合之后，细胞需在添加了氨甲蝶呤[54]或氨基蝶呤[55]的培养基中培养，以防止二氢叶酸还原酶阻碍一磷酸胸苷的重新合成。培养基一般选用HAT培养基（含有次黄嘌呤，氨基蝶呤，胸腺嘧啶脱氧核苷）。 胸苷激酶阴性细胞系中的未融合细胞将由于一磷酸胸苷的断供而死亡。而未融合淋巴细胞的死亡则是由于它们不是“不朽”的（不具备肿瘤细胞的无限分裂能力）。只有杂交瘤细胞由于同时继承了肿瘤细胞系的“不朽”和B淋巴细胞的胸苷激酶得以幸存。这样，可以用于生产所需抗体的杂交瘤细胞就筛选出来了，在培养后用于生产单克隆抗体。[56][57][58][59][60]

不过，采用相同原理，也可以通过筛选另一种次黄嘌呤-鸟嘌呤磷酸核糖转移酶（HGPRT）细胞系来达到筛选杂交瘤细胞的目的从而替代胸苷激酶，该酶在补救合成途经中调控鸟嘌呤核苷酸合成所必须的次黄嘌呤的合成。

应用案例

临床应用

胸苷激酶是一种补救酶，仅在细胞分裂前出现。由于细胞具有特殊的调控机制能够降解细胞分裂后不再需要的酶和蛋白，所以在正常的细胞分裂后，胸苷激酶不会从细胞释放。[61]因此一般条件下，血清或血浆中的胸苷激酶含量很低。肿瘤细胞释放胸苷激酶进入循环系统，可能是与已经死亡或即将死亡的肿瘤细胞的瓦解有关。因此，血清胸苷激酶水平能够用来评估肿瘤的增殖程度，并可以此来直接评估肿瘤的攻击力。有一个令人关注的情况，存在于循环系统中的胸苷激酶与基因编码的酶并不一致：基因编码的酶分子量为25kD。二聚体分子量为50kD，被ATP激活转化为四聚体后，分子量为100kD。[62]而循环系统中具有活性的酶的分子量为730kD，很有可能是与其他蛋白绑定形成了复合物[63] 。

目前胸苷激酶检测在临床应用中的价值主要体现在以下几点：

1、评估放化疗效果：由于胸苷激酶水平与肿瘤细胞恶性增殖程度具有相关性，治疗前后的胸苷激酶水平变化情况能为治疗评估提供辅助参考；

2、评估手术效果：通过比较肿瘤患者手术前后肿瘤细胞的增殖情况，为手术效果评价提供参考；

3、评估肿瘤复发风险：对肿瘤患者手术及治疗恢复期的残留肿瘤细胞的增殖状态进行动态评估，较影像学更早发现复发转移风险。[64]

不同肿瘤类别的胸苷激酶应用案例：

1、血液学恶性肿瘤中胸苷激酶的增长具有规律性。例如，胸苷激酶1（TK1）用于监控非霍奇金淋巴瘤。这种肿瘤的攻击性差别很大，有些属于慢速增殖，很难觉察难以及时治疗；还有一些属于快速增殖，具有高攻击性需要紧急治疗。这些差异可以在血清胸苷激酶的水平高低上得以体现，与正常水平相近的对应慢速增殖肿瘤，具有很高水平的对应快速增殖肿瘤。[65][66][67][68][69][70][71][72] 淋巴瘤患者血清TK1水平升高，可能预示着肿瘤具有高活性和高攻击性，因此通过监测血清TK1水平的变化，适合于肿瘤的治疗评估。[73]

该模型也使用于其他类型血液恶性肿瘤中（白血病[74][75][76]，浆细胞骨髓瘤[77][78]，骨髓增生异常综合症）。需要关注的是在骨髓增生异常综合症中：有一部分病例会迅速转变为进行白血病，但是还有一些在很长一段时间内进展缓慢。那如果能够鉴别出是否有进展为白血病的趋势将对治疗非常重要。

2、实体肿瘤中胸苷激酶的升高往往也与肿瘤恶性增殖程度，治疗效果，复发情况具有相关性[79][80][81][82]。有报告指出在前列腺癌症中，胸苷激酶能够如同PSA（前列腺特异抗原，目前前列腺癌中使用最频繁的肿瘤标志物）一样提供辅助参考。PSA提示肿瘤大小，而TK提示肿瘤增殖速度[83][84][85][86]。对于其他实体肿瘤，如小细胞肺癌[87][88][89]，乳腺癌[90][91][92]，胃癌[93]，肾癌[94]，膀胱癌[95]等都有应用价值。

非恶性肿瘤而造成血清胸苷激酶升高的原因有维生素B12缺乏引起的恶性贫血，[96][97]病毒感染（部分由于疱疹病毒）[97][98][99] 或正处于创伤、手术恢复期[100]。

恶性增殖风险评估

由于胸苷激酶1与细胞增殖的相关性，近些年来，有关于胸苷激酶1对于进展期癌前病变的检测意义，及在癌症预防体检中的应用价值的探讨。

有研究指出胸苷激酶1水平高低与不同年龄结构，及所处不同生活、工作环境的肿瘤发生风险具有相关性，在进行长期跟踪后，TK1水平的持续升高与所患癌前病变的恶性进程具有相关性，在早期恶性肿瘤病变预防中能够发挥一定作用。[101][102]

治疗

有些药物专门针对分裂期细胞有效。一般被用来治疗肿瘤和病毒性疾病（同时作用于逆转录病毒和其他病毒），这是由于病变细胞比正常细胞复制更快更频繁，同时也会杀死一些复制迅速地非恶性肿瘤细胞。

有不同种类的药物可以控制细胞分裂过快，能够直接作用于胸苷代谢也因此与胸苷激酶有关联[103][104][105][106]：

胸苷类似物作为DNA链终止物进入DNA链复制，但是由于结构已经改变所以抑制了DNA链的延长。作为胸苷类似物，更容易磷酸化生成5’-一磷酸复合物。一磷酸复合物进一步磷酸化生成三磷酸复合物参与到DNA链的复制。但类似物结构有所变化，一般不具有DNA链复制所必须的3’端羟基。如：叠氮胸苷（AZT；ATC：J05AF01）的3’端羟基被叠氮基替代；[107][108] 双脱氧胸苷（ATC：J05AF04）能够竞争性抑制胸苷。[109][110] AZT在一种检测血清胸苷激酶的方法中被用做底物。[111] 这意味着AZT会干扰这一步骤或是作为一种抑制剂： AZT是针对HIV（艾滋病病毒）感染的HAART（Highly Active Antiretroviral Therapy 高活性抗逆转录病毒疗法）疗法的组分之一。AIDS的最终结果一般是淋巴癌，而胸苷激酶检测的一项最重要的诊断应用就是监控淋巴癌。

酶底物类似物的化学结构

其他胸苷类似物，如碘苷（ATC：J05AB02）能够在随后的复制循环中阻碍基础配对，最终导致DNA合成链缺陷。[112]此物质结合化疗能够达到促使恶性肿瘤细胞凋亡的目的。[113]

一些抗病毒药物，如阿昔洛韦（ATC：J05AB01）和更昔洛韦（ATC：J05AB06）与其他一些研究成功的核酸类似物一样，[114]则是利用了对病毒胸苷激酶而非对人胸苷激酶的专属特异性。[115]这些药物机理如同前体药物，本身不具有毒性，但是被病毒胸苷激酶磷酸化后，会转变为细胞毒性药物。感染了病毒的细胞由于产生出高细胞毒性的三磷酸核苷最终导致细胞的凋亡。而相反的，人胸苷激酶由于其专属特异性，不会磷酸化而激活前体药物。因此，只有感染了病毒的细胞对药物敏感。这些药物仅对具有特异的疱疹病毒类胸苷激酶的病毒有效。[116]

自1979年12月，WHO宣布天花病毒已经根除之后，牛痘接种项目也已经终止了。该病毒如果由于意外事故或被作为生化武器重新出现，将会在毫无防备的人群中爆发性传播而难以控制。接种牛痘似乎是不道德的，因为唯一对天花有效的疫苗本身就含有用于刺激机体产生免疫效果反应的活性牛痘病毒。但出于安全问题考虑，有大量的疫苗需要长期储备，其中以高效的抗天花药物最为优先。一种可能的方式是利用痘病毒胸苷激酶的特异性来达到目的，作用机理与抗疱疹病毒类药物类似。有一个难点是痘病毒胸苷激酶与人胸苷激酶属于同一家族谱系，化学结构相似。目前痘病毒的结构已经探明并正在寻找潜在的抗病毒药物。[117]但有效的抗痘病毒药物研究尚无结果。

疱疹病毒胸苷激酶基因也当做“自杀基因”作为基因治疗实验中的安全系统，诱导细胞表达该基因后被更昔洛韦杀死。此种方法适用于通过重组基因诱发突变而最终导致的细胞增殖失控（诱导突变）。这些突变细胞产生的胸苷激酶扩散入周围细胞中，会导致周围细胞同样对更昔洛韦敏感，该现象称为“旁观者效应”。此方法已用于动物体的肿瘤治疗，有10%的恶性肿瘤细胞表达该基因并会被有效杀死。[118][119]利用一些肿瘤所特有的物质（肿瘤标志物）也能实现类似的胸苷激酶应用。这些肿瘤标志物，如CEA（癌胚抗原）和AFP（甲胎蛋白）。将这些肿瘤标志物的基因作为胸苷激酶的启动基因。胸苷激酶将在表达肿瘤标志物基因的细胞中被激活，在正常细胞中则不会，因此使用更昔洛韦治疗只会杀死肿瘤细胞。[120][121][122][123][124][125]尽管如此，这些基因治疗方法仍在实验阶段，一些与基因转移相关的问题，还未完全解决。

一种含硼元素的胸苷类似物已经被建议并用于BNCT法（硼-中子交互放射疗法）治疗脑部肿瘤的动物实验。[126][127][128][129][130][131][132][133][134][135][136]

检测方法

血清学

血清胸苷激酶检测主要是检测胸苷激酶1（TK1），检测方法目前主要有两类，一种是酶活性测定法；一种是酶浓度测定法。

使用酶活性测定法，一般通过将血清样本和底物类似物共同培养来实现。最初的商业可行性技术是使用碘代脱氧尿苷，即使用放射性碘替代了胸苷的一个甲基。[137][138][139]该底物能够被酶很好的识别。一磷酸化的碘代脱氧尿苷被添加在培养基中的氧化铝所吸附。在倾倒和洗脱后，氧化铝的放射性可换算出样本中胸苷激酶的量。应用此原理的商业试剂盒由贝克曼公司和索灵公司提供。

此外索灵公司还研究出一种非放射性分析方法。在该技术中3’-叠氮-2’，3’-脱氧胸苷（AZT：叠氮胸苷）首先被样本中的TK1磷酸化生成5’-一磷酸-AZT（AZTMP：叠氮胸苷一磷酸）。AZTMP通过免疫学方法测定，使用抗-AZTMP抗体为AZTMP标记上过氧化物。测定需在索灵公司提供的封闭式实验工作系统内进行。[140][111]

另一种新研发的技术是使用胸苷类似物——溴化尿苷，作为酶底物。反应产物（在微量滴定板中）吸附在滴定板各孔的底部。再通过ELISA方法测定：在各孔中加入抗溴化尿苷的单克隆抗体溶液。单克隆抗体上结合有碱性磷酸酶。洗脱掉过量的结合有碱性磷酸酶的抗体，加入含有碱性磷酸酶底物——4-硝基苯酚的溶液。反应产物4-硝基酚在磷酸pH环境中是黄色能够通过光度法测定。[141]此种分析方法能够进行更加灵敏的检测。商业试剂盒由Biovica公司提供。

使用酶浓度测定法，一般对抗TK1抗体的灵敏度要求很高，之前很长一段时间内没有突破。20世纪末至21世纪初，瑞典karolinska医学院利用鸟类特异性IgY抗体，开发出一种新型多克隆抗体——抗人TK1-IgY抗体，并申请了国际专利，此抗体具有很高的灵敏度和特异性，能够识别人血清中低浓度TK1。[142]此抗体在结合化学发光检测技术后，进一步提高了检测灵敏度。商用试剂盒由SSTK公司（中国，深圳）提供。

组织学

从组织提取物样本中能够检测到胸苷激酶。但尚没有标准的组织提取或分析方法，组织和细胞提取物中的TK检测与实际临床问题的相关性也未得到证实。见Romain等[143]和Arnér等[144]。有一种方法使用5’-溴-2’-脱氧尿苷作为底物类似物特异性检测细胞提取物中的TK2。[145]但在使用此方法的其他研究中，报告的结果差异很大方法可行性不佳。

处于发展阶段的胎儿组织的TK1水平比之后要高。[146][147][148]

某些非恶性肿瘤细胞和组织中的TK1水平也会出现明显升高：如存在单核细胞增多症时的周围淋巴细胞，[149]和存在恶性贫血是的骨髓细胞。[150][151]

由于TK1存在于处于分裂期的细胞中，因此有理由认为恶性肿瘤组织中的TK活性应比正常组织中的要高。这已在大部分的研究中得到证实。肿瘤组织中TK活性比一般组织要高[146][152][153][154]，如脑瘤[155]，血液系统恶性肿瘤[156]，结肠癌和结肠息肉[157][158][159][160][161][162]，乳腺癌[163][164][165][166][167][168]，肺癌[169][170][171]，胃癌[172]，卵巢癌[173]，间皮瘤[174]，黑色素瘤[175]，和甲状腺肿瘤[176][177]。

对于白血病[178][179]和乳腺癌[180]，治疗对细胞增殖速率的影响与对TK值的影响是由相关性的。

免疫组织化学染色

抗胸苷激酶抗体可以用于免疫组化检测。[181]胸苷激酶染色就是一种可靠的用于鉴别2期乳腺癌患者的技术。胸苷激酶和Ki-67染色技术的联合使用已经使相当多的患者得到了诊断。[182][183]

该技术对肺癌[182][184]，结直肠癌[185]，非小细胞肺癌[186]和肾癌[187]具有同样价值。

标签

胸苷激酶1；疱疹病毒胸苷激酶；胸苷酸激酶；二磷酸核苷激酶；胸苷酸合成酶

参考文献

  1. ^ PDB 2B8T; Kosinska U, Carnrot C, Eriksson S, Wang L, Eklund H. Structure of the substrate complex of thymidine kinase from Ureaplasma urealyticum and investigations of possible drug targets for the enzyme. FEBS J. December 2005, 272 (24): 6365–72. PMID 16336273. doi:10.1111/j.1742-4658.2005.05030.x. 
  2. ^ Kit S (December 1985). "Thymidine kinase". Microbiol. Sci. 2 (12): 369–75.
  3. ^ Wintersberger E (February 1997). "Regulation and biological function of thymidine kinase". Biochem. Soc. Trans. 25 (1): 303–8.
  4. ^ Reichard P, Estborn B (February 1951). "Utilization of desoxyribosides in the synthesis of polynucleotides". J. Biol. Chem. 188 (2): 839–46.
  5. ^ Kornberg A, Lehman IR, Simms ES (1956). "Polydeoxyribonucleotide synthesis by enzymes from Eschrichia coli". Fed. Proc. 15: 291–2.
  6. ^ Bollum FJ, Van Potter R (August 1958). "Incorporation of thymidine into deoxyribonucleic acid by enzymes from rat tissues". J. Biol. Chem. 233 (2): 478–82.
  7. ^ Weissman SM, Smellie RMS, Paul J (December 1960). "Studies on the biosynthesis of deoxyribonucleic acid by extracts of mammalian cells. IV. The phosphorylation of thymidine". Biochim. Biophys. Acta 45: 101–10.
  8. ^ Boyle DB, Gibbs AJ, Seigman LJ, Both GW, Coupar BE (1987). "Fowlpox virus thymidine kinase: nucleotide sequence and relationships to other thymidine kinases". Virology 156 (2): 355–365.
  9. ^ Lopez-Otin C, Blasco R, Vinuela E, Munoz M, Simon-Mateo C, Bockamp EO (1990). "Sequence and evolutionary relationships of African swine fever virus thymidine kinase". Virology 178 (1): 301–304.
  10. ^ Littlefield JW (February 1966). "The periodic synthesis of thymidine kinase in mouse fibroblasts". Biochim. Biophys. Acta 114 (2): 398–403
  11. ^ Bello LJ (December 1974). "Regulation of thymidine kinase synthesis in human cells". Exp. Cell Res. 89 (2): 263–74.
  12. ^ Berk AJ, Clayton DA (April 1973). "A genetically distinct thymidine kinase in mammalian mitochondria. Exclusive labeling of mitochondrial deoxyribonucleic acid". J. Biol. Chem. 248 (8): 2722–9.
  13. ^ Berk AJ, Meyer BJ, Clayton DA (February 1973). "Mitochondrial-specific thymidine kinase". Arch. Biochem. Biophys. 154 (2): 563–5.
  14. ^ Elsevier SM, Kucherlapati RS, Nichols EA, Creagan RP, Giles RE, Ruddle FH, Willecke K, McDougall JK (October 1974). "Assignment of the gene for galactokinase to human chromosome 17 and its regional localisation to band q21-22". Nature 251 (5476): 633–6.
  15. ^ Willecke K, Teber T, Kucherlapati RS, Ruddle FH (May 1977). "Human mitochondrial thymidine kinase is coded for by a gene on chromosome 16 of the nucleus". Somatic Cell Genet. 3 (3): 237–45
  16. ^ Flemington E, Bradshaw HD, Traina-Dorge V, Slagel V, Deininger PL (1987). "Sequence, structure and promoter characterization of the human thymidine kinase gene". Gene 52 (2–3): 267–77.
  17. ^ Welin M, Kosinska U, Mikkelsen NE, et al. (December 2004). "Structures of thymidine kinase 1 of human and mycoplasmic origin". Proc. Natl. Acad. Sci. U.S.A. 101 (52): 17970–5.
  18. ^ Munch-Petersen B, Cloos L, Jensen HK, Tyrsted G (1995). "Human thymidine kinase 1. Regulation in normal and malignant cells". Adv. Enzyme Regul. 35: 69–89.
  19. ^ Li CL, Lu CY, Ke PY, Chang ZF (January 2004). "Perturbation of ATP-induced tetramerization of human cytosolic thymidine kinase by substitution of serine-13 with aspartic acid at the mitotic phosphorylation site". Biochem. Biophys. Res. Commun. 313 (3): 587–93.
  20. ^ Zhu C, Harlow LS, Berenstein D, Munch-Petersen S, Munch-Petersen B (2006). "Effect of C-terminal of human cytosolic thymidine kinase (TK1) on in vitro stability and enzymatic properties". Nucleosides Nucleotides Nucleic Acids 25 (9–11): 1185–8.
  21. ^ 引用错误：没有为名为pmid7572355的参考文献提供内容
  22. ^ null Van Potter. FEEDBACK INHIBITION OF THYMIDINE KINASE BY THYMIDINE TRIPHOSPHATE. Experimental Cell Research. 1963, 24: SUPPL9:259–262 [2019-05-26]. ISSN 0014-4827. PMID 14046233. 
  23. ^ E. S. Severin, A. V. Itkes, O. N. Kartasheva, V. L. Tunitskaya, K. T. Turpaev, C. A. Kafiani. Regulation of 2-5 A phosphodiesterase activity by cAMP-dependent phosphorylation: mechanism and biological role. Advances in Enzyme Regulation. 1985, 23: 365–376 [2019-05-26]. ISSN 0065-2571. PMID 3000146. 
  24. ^ Nils Egil Mikkelsen, Kenth Johansson, Andreas Karlsson, Wolfgang Knecht, Gorm Andersen, Jure Piskur, Birgitte Munch-Petersen, Hans Eklund. Structural basis for feedback inhibition of the deoxyribonucleoside salvage pathway: studies of the Drosophila deoxyribonucleoside kinase. Biochemistry. 2003-05-20, 42 (19): 5706–5712 [2019-05-26]. ISSN 0006-2960. PMID 12741827. doi:10.1021/bi0340043. 
  25. ^ P. H. Fischer, A. W. Phillips. Antagonism of feedback inhibition. Stimulation of the phosphorylation of thymidine and 5-iodo-2'-deoxyuridine by 5-iodo-5'-amino-2',5'-dideoxyuridine. Molecular Pharmacology. 1984-5, 25 (3): 446–451 [2019-05-26]. ISSN 0026-895X. PMID 6727866. 
  26. ^ P. H. Fischer, M. A. Vazquez-Padua, C. A. Reznikoff. Perturbation of thymidine kinase regulation: a novel chemotherapeutic approach. Advances in Enzyme Regulation. 1986, 25: 21–34 [2019-05-26]. ISSN 0065-2571. PMID 3812083. 
  27. ^ P. H. Fischer, M. A. Vazquez-Padua, C. A. Reznikoff, W. J. Ratschan. Preferential stimulation of iododeoxyuridine phosphorylation by 5'-aminothymidine in human bladder cancer cells in vitro. Cancer Research. 1986-9, 46 (9): 4522–4526 [2019-05-26]. ISSN 0008-5472. PMID 3731105. 
  28. ^ P. H. Fischer, T. T. Fang, T. S. Lin, A. Hampton, J. Bruggink. Structure-activity analysis of antagonism of the feedback inhibition of thymidine kinase. Biochemical Pharmacology. 1988-04-01, 37 (7): 1293–1298 [2019-05-26]. ISSN 0006-2952. PMID 3355601. 
  29. ^ M. A. Vazquez-Padua, K. Kunugi, P. H. Fischer. Enzyme regulatory site-directed drugs: study of the interactions of 5'-amino-2', 5'-dideoxythymidine (5'-AdThd) and thymidine triphosphate with thymidine kinase and the relationship to the stimulation of thymidine uptake by 5'-AdThd in 647V cells. Molecular Pharmacology. 1989-1, 35 (1): 98–104 [2019-05-26]. ISSN 0026-895X. PMID 2536472. 
  30. ^ M. A. Vazquez-Padua, P. H. Fischer, B. J. Christian, C. A. Reznikoff. Basis for the differential modulation of the uptake of 5-iododeoxyuridine by 5'-aminothymidine among various cell types. Cancer Research. 1989-05-01, 49 (9): 2415–2421 [2019-05-26]. ISSN 0008-5472. PMID 2706629. （原始内容存档于2016-10-01）. 
  31. ^ M. A. Vázquez-Padua. Modulation of thymidine kinase activity: a biochemical strategy to enhance the activation of antineoplastic drugs. Puerto Rico Health Sciences Journal. 1994-3, 13 (1): 19–23 [2019-05-26]. ISSN 0738-0658. PMID 8016290. 
  32. ^ McKnight SL. The nucleotide sequence and transcript map of the herpes simplex virus thymidine kinase gene. Nucleic Acids Res. December 1980, 8 (24): 5949–64. PMC 328064  . PMID 6258156. doi:10.1093/nar/8.24.5949. 
  33. ^ Halliburton IW, Morse LS, Roizman B, Quinn KE. Mapping of the thymidine kinase genes of type 1 and type 2 herpes simplex viruses using intertypic recombinants. J. Gen. Virol. August 1980, 49 (2): 235–53. PMID 6255066. doi:10.1099/0022-1317-49-2-235. 
  34. ^ McDougall JK, Masse TH, Galloway DA. Location and cloning of the herpes simplex virus type 2 thymidine kinase gene. J. Virol. March 1980, 33 (3): 1221–4 [2012-03-01]. PMC 288658  . PMID 6245273. （原始内容存档于2011-08-07）. 
  35. ^ Kit S, Kit M, Qavi H, Trkula D, Otsuka H. Nucleotide sequence of the herpes simplex virus type 2 (HSV-2) thymidine kinase gene and predicted amino acid sequence of thymidine kinase polypeptide and its comparison with the HSV-1 thymidine kinase gene. Biochim. Biophys. Acta. November 1983, 741 (2): 158–70. PMID 6317035. doi:10.1016/0167-4781(83)90056-8. 
  36. ^ Sawyer MH, Ostrove JM, Felser JM, Straus SE. Mapping of the varicella zoster virus deoxypyrimidine kinase gene and preliminary identification of its transcript. Virology. February 1986, 149 (1): 1–9. PMID 3004022. doi:10.1016/0042-6822(86)90081-4. 
  37. ^ Littler E, Zeuthen J, McBride AA, Trøst Sørensen E, Powell KL, Walsh-Arrand JE, Arrand JR. Identification of an Epstein-Barr virus-coded thymidine kinase. EMBO J. August 1986, 5 (8): 1959–66. PMC 1167064  . PMID 3019675. 
  38. ^ Kit S, Dubbs DR. Acquisition of thymidine kinase activity by herpes simplex-infected mouse fibroblast cells. Biochem. Biophys. Res. Commun. April 1963, 11: 55–9. PMID 14033128. doi:10.1016/0006-291X(63)90027-5. 
  39. ^ Schlosser CA, Steglich C, deWet JR, Scheffler IE. Cell cycle-dependent regulation of thymidine kinase activity introduced into mouse LMTK- cells by DNA and chromatin-mediated gene transfer. Proc. Natl. Acad. Sci. U.S.A. February 1981, 78 (2): 1119–23. PMC 319958  . PMID 6940130. doi:10.1073/pnas.78.2.1119. 
  40. ^ Coppock DL, Pardee AB. Control of thymidine kinase mRNA during the cell cycle. Mol. Cell. Biol. August 1987, 7 (8): 2925–32 [2012-03-01]. PMC 367911  . PMID 3670299. （原始内容存档于2011-09-27）. 
  41. ^ Stewart CJ, Ito M, Conrad SE. Evidence for transcriptional and post-transcriptional control of the cellular thymidine kinase gene. Mol. Cell. Biol. March 1987, 7 (3): 1156–63 [2012-03-01]. PMC 365188  . PMID 3561412. （原始内容存档于2011-09-27）. 
  42. ^ Piper AA, Tattersall MH, Fox RM. The activities of thymidine metabolising enzymes during the cell cycle of a human lymphocyte cell line LAZ-007 synchronised by centrifugal elutriation. Biochim. Biophys. Acta. December 1980, 633 (3): 400–9. PMID 6260157. 
  43. ^ Pelka-Fleischer R, Ruppelt W, Wilmanns W, Sauer H, Schalhorn A. Relation between cell cycle stage and the activity of DNA-synthesizing enzymes in cultured human lymphoblasts: investigations on cell fractions enriched according to cell cycle stages by way of centrifugal elutriation. Leukemia. March 1987, 1 (3): 182–7. PMID 3669741. 
  44. ^ Sherley JL, Kelly TJ. Regulation of human thymidine kinase during the cell cycle. J. Biol. Chem. June 1988, 263 (17): 8350–8 [2012-03-01]. PMID 3372530. （原始内容存档于2005-01-26）. 
  45. ^ Gross MK, Kainz MS, Merrill GF. The chicken thymidine kinase gene is transcriptionally repressed during terminal differentiation: the associated decline in TK mRNA cannot account fully for the disappearance of TK enzyme activity. Dev. Biol. August 1987, 122 (2): 439–51. PMID 3596017. doi:10.1016/0012-1606(87)90308-3. 
  46. ^ Kauffman MG, Kelly TJ. Cell cycle regulation of thymidine kinase: residues near the carboxyl terminus are essential for the specific degradation of the enzyme at mitosis. Mol. Cell. Biol. May 1991, 11 (5): 2538–46 [2012-03-01]. PMC 360023  . PMID 1708095. （原始内容存档于2011-09-27）. 
  47. ^ Sutterluety H, Bartl S, Karlseder J, Wintersberger E, Seiser C. Carboxy-terminal residues of mouse thymidine kinase are essential for rapid degradation in quiescent cells. J. Mol. Biol. June 1996, 259 (3): 383–92. PMID 8676376. doi:10.1006/jmbi.1996.0327. 
  48. ^ Johnson HA, Rubini JR, Cronkite EP, Bond VP. Labeling of human tumor cells in vivo by tritiated thymidine. Lab. Invest. 1960, 9: 460–5. PMID 14407455. 
  49. ^ Barthel H; Cleij MC; Collingridge DR; et al. 3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res. July 2003, 63 (13): 3791–8. PMID 12839975. 
  50. ^ Chao KS. Functional imaging for early prediction of response to chemoradiotherapy: 3'-deoxy-3'-18F-fluorothymidine positron emission tomography--a clinical application model of esophageal cancer. Semin. Oncol. December 2006, 33 (6 Suppl 11): S59–63. PMID 17178290. doi:10.1053/j.seminoncol.2006.10.011. 
  51. ^ Salskov A, Tammisetti VS, Grierson J, Vesselle H. FLT: measuring tumor cell proliferation in vivo with positron emission tomography and 3'-deoxy-3'-[18F]fluorothymidine. Semin Nucl Med. November 2007, 37 (6): 429–39. PMID 17920350. doi:10.1053/j.semnuclmed.2007.08.001. 
  52. ^ de Langen AJ; Klabbers B; Lubberink M; et al. Reproducibility of quantitative (18)F-3'-deoxy-3'-fluorothymidine measurements using positron emission tomography. Eur. J. Nucl. Med. Mol. Imaging. October 2008, 36 (3): 389–95. PMID 18931838. doi:10.1007/s00259-008-0960-5. 
  53. ^ Shields AF; Lawhorn-Crews JM; Briston DA; et al. Analysis and reproducibility of 3'-Deoxy-3'-[18F]fluorothymidine positron emission tomography imaging in patients with non-small cell lung cancer. Clin. Cancer Res. July 2008, 14 (14): 4463–8. PMID 18628460. doi:10.1158/1078-0432.CCR-07-5243. 
  54. ^ Methotrexate - Compound Summary. [2012-03-01]. （原始内容存档于2014-03-10）. 
  55. ^ Aminopterin - Compound Summary. [2012-03-01]. （原始内容存档于2014-03-10）. 
  56. ^ Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. August 1975, 256 (5517): 495–7. Bibcode:1975Natur.256..495K. PMID 1172191. doi:10.1038/256495a0. 
  57. ^ Köhler G, Howe SC, Milstein C. Fusion between immunoglobulin-secreting and nonsecreting myeloma cell lines. Eur. J. Immunol. April 1976, 6 (4): 292–5. PMID 825374. doi:10.1002/eji.1830060411. 
  58. ^ Köhler G, Milstein C. Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion. Eur. J. Immunol. July 1976, 6 (7): 511–9. PMID 825377. doi:10.1002/eji.1830060713. 
  59. ^ Köhler G, Pearson T, Milstein C. Fusion of T and B cells. Somatic Cell Genet. May 1977, 3 (3): 303–12. PMID 305123. doi:10.1007/BF01538748. 
  60. ^ Milstein C, Adetugbo K, Cowan NJ, Kohler G, Secher DS. Expression of antibody genes in tissue culture: structural mutants and hybrid cells. Natl Cancer Inst Monogr. May 1978, (48): 321–30. PMID 107455. 
  61. ^ 引用错误：没有为名为pmid4223355的参考文献提供内容
  62. ^ 引用错误：没有为名为pmid15611477的参考文献提供内容
  63. ^ Karlström AR, Neumüller M, Gronowitz JS, Källander CF. Molecular forms in human serum of enzymes synthesizing DNA precursors and DNA. Mol. Cell. Biochem. January 1990, 92 (1): 23–35. PMID 2155379. doi:10.1007/BF00220716. 
  64. ^ 刘秀菊，周际，李远等。TK1——一种新的肿瘤生长相关标志物的应用新进展。《中国药理学与毒理学杂志》2010年12月。
  65. ^ Ellims PH, Van der Weyden MB, Medley G. Thymidine kinase isoenzymes in human malignant lymphoma. Cancer Res. February 1981, 41 (2): 691–5. PMID 7448815. 
  66. ^ Hagberg H, Glimelius B, Gronowitz JS, Killander A, Källander CFR, Schröder T. Biochemical markers in non-Hodgkin's lymphoma stages III and IV and prognosis: a multivariate analysis. Scand J Haematol. July 1984, 33 (1): 59–67. PMID 6379852. doi:10.1111/j.1600-0609.1984.tb02211.x. 
  67. ^ Gronowitz JS, Hagberg H, Källander CFR, Simonsson B. The use of serum deoxythymidine kinase as a prognostic marker, and in the monitoring of patients with non-Hodgkin's lymphoma. Br. J. Cancer. April 1983, 47 (4): 487–95. PMC 2011337  . PMID 6849793. doi:10.1038/bjc.1983.78. 
  68. ^ Hallek M, Wanders L, Strohmeyer S, Emmerich B. Thymidine kinase: a tumor marker with prognostic value for non-Hodgkin's lymphoma and a broad range of potential clinical applications. Ann. Hematol. July 1992, 65 (1): 1–5. PMID 1643153. doi:10.1007/BF01715117. 
  69. ^ Bogni A, Cortinois A, Grasselli G; et al. Thymidine kinase (TK) activity as a prognostic parameter of survival in lymphoma patients. J. Biol. Regul. Homeost. Agents. 1994, 8 (4): 121–5. PMID 7660854. 
  70. ^ Rehn S, Gronowitz JS, Källander C, Sundström C, Glimelius B. Deoxythymidine kinase in the tumour cells and serum of patients with non-Hodgkin lymphomas. Br. J. Cancer. May 1995, 71 (5): 1099–105. PMC 2033808  . PMID 7734308. doi:10.1038/bjc.1995.213. 
  71. ^ Suki S, Swan F, Tucker S; et al. Risk classification for large cell lymphoma using lactate dehydrogenase, beta-2 microglobulin, and thymidine kinase. Leuk. Lymphoma. June 1995, 18 (1–2): 87–92. PMID 8580834. doi:10.3109/10428199509064927. 
  72. ^ Hallek M, Wanders L, Ostwald M; et al. Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. Leuk. Lymphoma. August 1996, 22 (5–6): 439–47. PMID 8882957. doi:10.3109/10428199609054782. 
  73. ^ Zhu-Lin Pan, Xing-Ying Ji, Yan-Min Shi, et al.(2010). " Serum thymidine kinase 1 concentration as a prognostic factor".J Cancer Res Clin Oncol.136:1193-1199.
  74. ^ Källander CFR, Simonsson B, Gronowitz JS, Nilsson K. Serum deoxythymidine kinase correlates with peripheral lymphocyte thymidine uptake in chronic lymphocytic leukemia. Eur. J. Haematol. April 1987, 38 (4): 331–7. PMID 3609253. doi:10.1111/j.1600-0609.1987.tb00007.x. 
  75. ^ Källander CFR, Simonsson B, Hagberg H, Gronowitz JS. Serum deoxythymidine kinase gives prognostic information in chronic lymphocytic leukemia. Cancer. December 1984, 54 (11): 2450–5. PMID 6498737. doi:10.1002/1097-0142(19841201)54:11<2450::AID-CNCR2820541123>3.0.CO;2-R. 
  76. ^ A. Rivkina, G. Vitols, M. Murovska, S. Lejniece. Identifying the stage of new CLL patients using TK, ZAP-70, CD38 levels. Experimental Oncology. 2011-6, 33 (2): 99–103 [2019-05-26]. ISSN 1812-9269. PMID 21716207. （原始内容存档于2019-09-05）. 
  77. ^ Simonsson B, Källander CFR, Brenning G, Killander A, Gronowitz JS, Bergström R. Biochemical markers in multiple myeloma: a multivariate analysis. Br. J. Haematol. May 1988, 69 (1): 47–53. PMID 3289607. doi:10.1111/j.1365-2141.1988.tb07601.x. 
  78. ^ Simonsson B, Källander CFR, Brenning G, Killander A, Ahre A, Gronowitz JS. Evaluation of serum deoxythymidine kinase as a marker in multiple myeloma. Br. J. Haematol. October 1985, 61 (2): 215–24. PMID 4041368. doi:10.1111/j.1365-2141.1985.tb02820.x. 
  79. ^ Yan Chen, MinGang Ying, YanSong Chen, et al. (2010). “Serum thymidine kinase 1 correlates to clinical stages and clinical reactions and monitors the outcome of therapy of 1,247 cancer patients in routine clinical settings”. Int J Clin Oncol.
  80. ^ Zhishan Li, Yinghong Wang, Jie He, Jie Ma, et al. (March 2010). “Serological thymidine kinase 1 is a prognostic factor in oesophageal, cardial and lung carcinomas”. European Journal of Cancer Prevention 19:313-318.
  81. ^ Qimin He, PingGN Zhang, Li Zou, et al. (May 2005). “Concentration of thymidine kinase 1 in serum(S-TK1) is a more sensitive proliferation marker in human solid tumors than its activity". Oncology Reports 14: 1013-1019.
  82. ^ Zhenxin Wang, Bin Zhang, Bin Ni, Jin Zang. (September 2011). “Value of serum thymidine kinase 1 in evaluating the efficacy of malignant tumor treatment”. Jiangsu Med J, September 2011, Vol37, No.18:2174-2175.
  83. ^ Larson A, Fritjofsson A, Norlén BJ, Gronowitz JS, Ronquist G. Prostate specific acid phosphatase versus five other possible tumour markers: a comparative study in men with prostatic carcinoma. Scand. J. Clin. Lab. Invest. Suppl. 1985, 179: 81–8. PMID 2417306. 
  84. ^ Letocha H, Eklöv S, Gronowitz S, Norlén BJ, Nilsson S. Deoxythymidine kinase in the staging of prostatic adenocarcinoma. Prostate. July 1996, 29 (1): 15–9. PMID 8685050. doi:10.1002/(SICI)1097-0045(199607)29:1<15::AID-PROS2>3.0.CO;2-H. 
  85. ^ Lewenhaupt A, Ekman P, Eneroth P, Nilsson B. Tumour markers as prognostic aids in prostatic carcinoma. Br J Urol. August 1990, 66 (2): 182–7. PMID 1697204. doi:10.1111/j.1464-410X.1990.tb14900.x. 
  86. ^ Ekman P, Lewenhaupt A. Serum tumour markers in human prostatic carcinoma. The value of a marker panel for prognostic information. Acta Oncol. 1991, 30 (2): 173–5. PMID 2029401. doi:10.3109/02841869109092345. 
  87. ^ Gronowitz JS, Bergström R, Nôu E; et al. Clinical and serologic markers of stage and prognosis in small cell lung cancer. A multivariate analysis. Cancer. August 1990, 66 (4): 722–32. PMID 2167141. doi:10.1002/1097-0142(19900815)66:4<722::AID-CNCR2820660421>3.0.CO;2-J. 
  88. ^ Gronowitz JS, Steinholtz L, Källander CF, Hagberg H, Bergh J. Serum deoxythymidine kinase in small cell carcinoma of the lung. Relation to clinical features, prognosis, and other biochemical markers. Cancer. July 1986, 58 (1): 111–8. PMID 3011236. doi:10.1002/1097-0142(19860701)58:1<111::AID-CNCR2820580120>3.0.CO;2-K. 
  89. ^ H.X.Li, S Zhang, D.S Lei, X.Q Wang, et al. (August 2005). “Serum thymidine kinase 1 is a prognostic and monitoring factor in patients with non-small cell lung cancer”. Oncology Reports 13: 145-149.
  90. ^ Benjamin Nisman, Tanir Allweis, Luna Kaduri, Bella Maly, Simon Gronowitz, Tamar Hamburger, Tamar Peretz. Serum thymidine kinase 1 activity in breast cancer. Cancer Biomarkers: Section A of Disease Markers. 2010, 7 (2): 65–72 [2019-05-26]. ISSN 1875-8592. PMID 21178264. doi:10.3233/CBM-2010-0148. （原始内容存档于2019-09-05）. 
  91. ^ Q. He, L. Zou, P.A Zhang, et al. (2000) “The clinical significance of thymidine kinase 1 measurement in serum of breast cancer patients using anti-TK1 antibody”. J.Biol.Marker, 15:139-146
  92. ^ Qimin He, Tommy Fornander, Hemming Johansson, et al. (2006) “Thymidine kinase 1 in serum predicts increased risk of distant or loco-regional recurrence following surgery in patients with early breast cancer”. Anticancer Research 26: 4753-4760.
  93. ^ L. Zou, P.G Zhang, S. Zou, et al.(2002) “The half-life of thymidine kinase 1 in serum measured by ECL dot blot: a potential marker for monitoring the response to surgery of patients with gastric cancer”. The international Journal of biological Markers, Vol. 17 No. 2:135-140.
  94. ^ Benjamin Nisman, Vladimir Yutkin, Hovav Nechushtan, Ofer N. Gofrit, Tamar Peretz, Simon Gronowitz, Dov Pode. Circulating tumor M2 pyruvate kinase and thymidine kinase 1 are potential predictors for disease recurrence in renal cell carcinoma after nephrectomy. Urology. 2010-8, 76 (2): 513.e1–6 [2019-05-26]. ISSN 1527-9995. PMID 20573390. doi:10.1016/j.urology.2010.04.034. （原始内容存档于2019-09-05）. 
  95. ^ Jie Zhang, Quanan Jia, Shan Zou, et al. (August 2006). “Thymidine kinase 1: A proliferation marker of determining prognosis and monitoring the surgical outcome of primary bladder carcinoma patients”. Oncology Reports 15:455-461.
  96. ^ P. H. Ellims, R. J. Hayman, M. B. Van der Weyden. Expression of fetal thymidine kinase in human cobalamin or folate deficient lymphocytes. Biochemical and Biophysical Research Communications. 1979-07-12, 89 (1): 103–107 [2019-05-26]. ISSN 0006-291X. PMID 475797. 
  97. ^ 97.0 97.1 M. Neumuller, C. F. Källander, J. S. Gronowitz. Detection and characteristics of DNA polymerase activity in serum from patients with malignant, viral, or B12-deficiency disease. Enzyme. 1989, 41 (1): 6–16 [2019-05-26]. ISSN 0013-9432. PMID 2543552. 
  98. ^ G. Tufveson, T. H. Tötterman, C. F. Källander, A. Hagström, J. S. Gronowitz. Serum thymidine-kinase and cytomegalovirus-specific antibodies after renal transplantation. Transplantation Proceedings. 1988-6, 20 (3): 405–407 [2019-05-26]. ISSN 0041-1345. PMID 2837850. 
  99. ^ C. F. Källander, J. S. Gronowitz, E. Olding-Stenkvist. Rapid diagnosis of varicella-zoster virus infection by detection of viral deoxythymidine kinase in serum and vesicle fluid. Journal of Clinical Microbiology. 1983-2, 17 (2): 280–287 [2019-05-26]. ISSN 0095-1137. PMC 272623  . PMID 6339548. 
  100. ^ Zhishan Li, Yinghong Wang, Jie Ma, et al. (2010). “Transient increase in serum thymidine kinase 1 within one week after surgery of patients with carcinoma”. Anticancer Research 30: 1295-1300.
  101. ^ ZhiHeng Chen, Hui Zhou, ShengLan Li, et al. (2008). “Serological Thymidine Kinase 1 (STK1) indicates an elevated risk for the development of malignant tumors”. Anticancer Research 28:3897-3908.
  102. ^ Shouqing Huang, Jianzh Lin, Na Guo, et al. (2011). “Elevated serum thymidine kinase 1 predicts risk of pre/early cancerous progression”. Asian Pacific J Cancer Prev, 12, 497-505.
  103. ^ Lin TS, Neenan JP, Cheng YC, Prusoff WH. Synthesis and antiviral activity of 5- and 5'-substituted thymidine analogs. J. Med. Chem. April 1976, 19 (4): 495–8. PMID 177781. doi:10.1021/jm00226a009. 
  104. ^ Helgstrand E, Oberg B. Enzymatic targets in virus chemotherapy. Antibiot Chemother. 1980, 27: 22–69. PMID 6996606. 
  105. ^ Shannon WM, Schabel FM. Antiviral agents as adjuncts in cancer chemotherapy. Pharmacol. Ther. 1980, 11 (2): 263–390. PMID 7001501. doi:10.1016/0163-7258(80)90034-0. 
  106. ^ Hirsch MS. Chemotherapy of human immunodeficiency virus infections: current practice and future prospects. J. Infect. Dis. May 1990, 161 (5): 845–57. PMID 1691243. doi:10.1093/infdis/161.5.845. 
  107. ^ Shiau GT, Schinazi RF, Chen MS, Prusoff WH. Synthesis and biological activities of 5-(hydroxymethyl, azidomethyl, or aminomethyl)-2'-deoxyuridine and related 5'-substituted analogues. J. Med. Chem. February 1980, 23 (2): 127–33. PMID 6244411. doi:10.1021/jm00176a005. 
  108. ^ Mitsuya H, Weinhold KJ, Furman PA; et al. 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc. Natl. Acad. Sci. U.S.A. October 1985, 82 (20): 7096–100. PMC 391317  . PMID 2413459. doi:10.1073/pnas.82.20.7096. 
  109. ^ Baba M, Pauwels R, Herdewijn P, De Clercq E, Desmyter J, Vandeputte M. Both 2',3'-dideoxythymidine and its 2',3'-unsaturated derivative (2',3'-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro. Biochem. Biophys. Res. Commun. January 1987, 142 (1): 128–34 [2012-03-13]. PMID 3028398. doi:10.1016/0006-291X(87)90460-8. （原始内容存档于2020-05-29）. 
  110. ^ Hamamoto Y, Nakashima H, Matsui T, Matsuda A, Ueda T, Yamamoto N. Inhibitory effect of 2',3'-didehydro-2',3'-dideoxynucleosides on infectivity, cytopathic effects, and replication of human immunodeficiency virus. Antimicrob. Agents Chemother. June 1987, 31 (6): 907–10. PMC 284209  . PMID 3039911. 
  111. ^ 111.0 111.1 Ohrvik A, Lindh M, Einarsson R, Grassi J, Eriksson S. Sensitive nonradiometric method for determining thymidine kinase 1 activity. Clin. Chem. September 2004, 50 (9): 1597–606. PMID 15247154. doi:10.1373/clinchem.2003.030379. 
  112. ^ Prusoff WH. Synthesis and biological activities of iododeoxyuridine, an analog of thymidine. Biochim. Biophys. Acta. March 1959, 32 (1): 295–6. PMID 13628760. doi:10.1016/0006-3002(59)90597-9. 
  113. ^ Morgenroth A, Deisenhofer S, Glatting G; et al. Preferential Tumor Targeting and Selective Tumor Cell Cytotoxicity of 5-[131/125I]Iodo-4'-Thio-2'-Deoxyuridine. Clin. Cancer Res. November 2008, 14 (22): 7311–9. PMID 19010846. doi:10.1158/1078-0432.CCR-08-0907. 
  114. ^ Graciela Andrei, Robert Snoeck. Emerging drugs for varicella-zoster virus infections. Expert Opinion on Emerging Drugs. 2011-9, 16 (3): 507–535 [2019-05-26]. ISSN 1744-7623. PMID 21699441. doi:10.1517/14728214.2011.591786. （原始内容存档于2011-07-03）. 
  115. ^ Johnson VA, Hirsch MS. New developments in antiretroviral drug therapy for human immunodeficiency virus infections. Ganciclover is a 5' monophosphate that does not require thymidine kinase activation and thus expresses higher toxicity to host enzymes due to a decrease in selectivity. AIDS Clin Rev. 1990: 235–72. PMID 1707295. 
  116. ^ Mar EC, Chiou JF, Cheng YC, Huang ES. Inhibition of cellular DNA polymerase alpha and human cytomegalovirus-induced DNA polymerase by the triphosphates of 9-(2-hydroxyethoxymethyl)guanine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine. J. Virol. March 1985, 53 (3): 776–80. PMC 254706  . PMID 2983088. 
  117. ^ Black ME, Hruby DE. Quaternary structure of vaccinia virus thymidine kinase. Biochem. Biophys. Res. Commun. June 1990, 169 (3): 1080–6 [2012-03-13]. PMID 2114104. doi:10.1016/0006-291X(90)92005-K. （原始内容存档于2015-09-24）. 
  118. ^ Nicholas TW, Read SB, Burrows FJ, Kruse CA. Suicide gene therapy with Herpes simplex virus thymidine kinase and ganciclovir is enhanced with connexins to improve gap junctions and bystander effects. Histol. Histopathol. April 2003, 18 (2): 495–507 [2012-03-13]. PMID 12647801. （原始内容存档于2020-07-23）. 
  119. ^ Ellen Preuss, Alexander Muik, Kristoffer Weber, Jürgen Otte, Dorothee von Laer, Boris Fehse. Cancer suicide gene therapy with TK.007: superior killing efficiency and bystander effect. Journal of Molecular Medicine (Berlin, Germany). 2011-11, 89 (11): 1113–1124 [2019-05-26]. ISSN 1432-1440. PMID 21698427. doi:10.1007/s00109-011-0777-8. （原始内容存档于2019-01-06）. 
  120. ^ Hart IR. Tissue specific promoters in targeting systemically delivered gene therapy. Semin. Oncol. February 1996, 23 (1): 154–8. PMID 8607025. 
  121. ^ Wills KN, Huang WM, Harris MP, Machemer T, Maneval DC, Gregory RJ. Gene therapy for hepatocellular carcinoma: chemosensitivity conferred by adenovirus-mediated transfer of the HSV-1 thymidine kinase gene. Cancer Gene Ther. September 1995, 2 (3): 191–7. PMID 8528962. 
  122. ^ Ido A, Nakata K, Kato Y; et al. Gene therapy for hepatoma cells using a retrovirus vector carrying herpes simplex virus thymidine kinase gene under the control of human alpha-fetoprotein gene promoter. Cancer Res. July 1995, 55 (14): 3105–9. PMID 7541712. 
  123. ^ Kanai F, Shiratori Y, Yoshida Y; et al. Gene therapy for alpha-fetoprotein-producing human hepatoma cells by adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene. Hepatology. June 1996, 23 (6): 1359–68. PMID 8675152. doi:10.1002/hep.510230611. 
  124. ^ Garver RI, Goldsmith KT, Rodu B, Hu PC, Sorscher EJ, Curiel DT. Strategy for achieving selective killing of carcinomas. Gene Ther. January 1994, 1 (1): 46–50. PMID 7584059. 
  125. ^ Hart IR. Transcriptionally targeted gene therapy. Curr. Top. Microbiol. Immunol. 1996, 213 (3): 19–25. PMID 8815006. 
  126. ^ {{cite journal |author=Byun Y, Thirumamagal BT, Yang W, Eriksson S, Barth RF, Tjarks W |title=Preparation and biological evaluation of 10B-enriched 3-[5-{2-(2,3-dihydroxyprop-1-yl)-o-carboran-1-yl}pentan-1-yl]thymidine (N5-2OH), a new boron delivery agent for boron neutron capture therapy of brain tumors |journal=J. Med. Chem. |volume=49 |issue=18 |pages=5513–23 |pmid=16942024 |doi=10.1021/jm060413w |url=|date=September 2006}}
  127. ^ Thirumamagal BT, Johnsamuel J, Cosquer GY; et al. Boronated thymidine analogues for boron neutron capture therapy. Nucleosides Nucleotides Nucleic Acids. 2006, 25 (8): 861–6. PMID 16901817. doi:10.1080/15257770600793844. 
  128. ^ Narayanasamy S, Thirumamagal BT, Johnsamuel J; et al. Hydrophilically enhanced 3-carboranyl thymidine analogues (3CTAs) for boron neutron capture therapy (BNCT) of cancer. Bioorg. Med. Chem. October 2006, 14 (20): 6886–99. PMID 16831554. doi:10.1016/j.bmc.2006.06.039. 
  129. ^ Byun Y, Narayanasamy S, Johnsamuel J; et al. 3-Carboranyl thymidine analogues (3CTAs) and other boronated nucleosides for boron neutron capture therapy. Anticancer Agents Med Chem. March 2006, 6 (2): 127–44. PMID 16529536. doi:10.2174/187152006776119171. [永久失效链接]
  130. ^ Byun Y, Yan J, Al-Madhoun AS; et al. Synthesis and biological evaluation of neutral and zwitterionic 3-carboranyl thymidine analogues for boron neutron capture therapy. J. Med. Chem. February 2005, 48 (4): 1188–98. PMID 15715485. doi:10.1021/jm0491896. 
  131. ^ Barth RF, Yang W, Al-Madhoun AS; et al. Boron-containing nucleosides as potential delivery agents for neutron capture therapy of brain tumors. Cancer Res. September 2004, 64 (17): 6287–95. PMID 15342417. doi:10.1158/0008-5472.CAN-04-0437. 
  132. ^ Al-Madhoun AS, Johnsamuel J, Barth RF, Tjarks W, Eriksson S. Evaluation of human thymidine kinase 1 substrates as new candidates for boron neutron capture therapy. Cancer Res. September 2004, 64 (17): 6280–6. PMID 15342416. doi:10.1158/0008-5472.CAN-04-0197. 
  133. ^ Johnsamuel J, Lakhi N, Al-Madhoun AS; et al. Synthesis of ethyleneoxide modified 3-carboranyl thymidine analogues and evaluation of their biochemical, physicochemical, and structural properties. Bioorg. Med. Chem. September 2004, 12 (18): 4769–81. PMID 15336255. doi:10.1016/j.bmc.2004.07.032. 
  134. ^ Byun Y, Yan J, Al-Madhoun AS; et al. The synthesis and biochemical evaluation of thymidine analogues substituted with nido carborane at the N-3 position. Appl Radiat Isot. November 2004, 61 (5): 1125–30. PMID 15308203. doi:10.1016/j.apradiso.2004.05.023. 
  135. ^ Yan J, Naeslund C, Al-Madhoun AS; et al. Synthesis and biological evaluation of 3'-carboranyl thymidine analogues. Bioorg. Med. Chem. Lett. August 2002, 12 (16): 2209–12 [2012-03-13]. PMID 12127539. doi:10.1016/S0960-894X(02)00357-8. （原始内容存档于2018-07-02）. 
  136. ^ Barth RF, Yang W, Wu G; et al. Thymidine kinase 1 as a molecular target for boron neutron capture therapy of brain tumors. Proc. Natl. Acad. Sci. U.S.A. November 2008, 105 (45): 17493–7. PMC 2582264  . PMID 18981415. doi:10.1073/pnas.0809569105. 
  137. ^ Gronowitz JS, Källander CF. Optimized assay for thymidine kinase and its application to the detection of antibodies against herpes simplex virus type 1- and 2-induced thymidine kinase. Infect. Immun. August 1980, 29 (2): 425–34. PMC 551136  . PMID 6260651. 
  138. ^ Gronowitz JS, Källander FR, Diderholm H, Hagberg H, Pettersson U. Application of an in vitro assay for serum thymidine kinase: results on viral disease and malignancies in humans. Int. J. Cancer. January 1984, 33 (1): 5–12. PMID 6693195. doi:10.1002/ijc.2910330103. 
  139. ^ Gronowitz JS, Källander CF. A sensitive assay for detection of deoxythymidine kinase and its application to herpesvirus diagnosis. Curr. Top. Microbiol. Immunol. 1983, 104: 235–45. PMID 6307593. 
  140. ^ 引用错误：没有为名为pmid16140350的参考文献提供内容
  141. ^ Gronowitz, JS (24.2.2006) A method and kit for determination of thymidine kinase activity and use thereof. International patent application PCT/SE2006/000246
  142. ^ Chuanjing Wu, Rong-jiang Yang, Ji Zhou, et al. (February 2003). “Production and characterization of a novel chicken IgY antibody raised against C-terminal peptide from human thymidine kinase 1”. Journal of Immunological Methods 277:157-169.
  143. ^ Romain S, Spyratos F, Guirou O, Deytieux S, Chinot O, Martin PM. Technical evaluation of thymidine kinase assay in cytosols from breast cancers. EORTC Receptor Study Group Report. Eur. J. Cancer. 1994, 30A (14): 2163–5. PMID 7857717. doi:10.1016/0959-8049(94)00376-G. 
  144. ^ Arnér ES, Spasokoukotskaja T, Eriksson S. Selective assays for thymidine kinase 1 and 2 and deoxycytidine kinase and their activities in extracts from human cells and tissues. Biochem. Biophys. Res. Commun. October 1992, 188 (2): 712–8. PMID 1359886. doi:10.1016/0006-291X(92)91114-6. 
  145. ^ Wang L, Eriksson S. 5-Bromovinyl 2'-deoxyuridine phosphorylation by mitochondrial and cytosolic thymidine kinase (TK2 and TK1) and its use in selective measurement of TK2 activity in crude extracts. Nucleosides Nucleotides Nucleic Acids. June 2008, 27 (6): 858–62. PMID 18600552. doi:10.1080/15257770802146510. 
  146. ^ 146.0 146.1 Herzfeld A, Greengard O. Enzyme activities in human fetal and neoplastic tissues. Cancer. November 1980, 46 (9): 2047–54. PMID 6253048. doi:10.1002/1097-0142(19801101)46:9<2047::AID-CNCR2820460924>3.0.CO;2-Q. 
  147. ^ Machovich R, Greengard O. Thymidine kinase in rat tissues during growth and differentiation. Biochim. Biophys. Acta. December 1972, 286 (2): 375–81. PMID 4660462. doi:10.1016/0304-4165(72)90273-5. 
  148. ^ Herzfeld A, Raper SM, Gore I. The ontogeny of thymidine kinase in tissues of man and rat. Pediatr. Res. December 1980, 14 (12): 1304–10. PMID 7208144. doi:10.1203/00006450-198012000-00006. 
  149. ^ Schollenberger S, Taureck D, Wilmanns W. [Enzymes of thymidine and thymidylate metabolism in normal and pathological blood and bone marrow cells] [Enzymes of thymidine and thymidylate metabolism in normal and pathological blood and bone marrow cells]. Blut. November 1972, 25 (5): 318–34. PMID 4508724. doi:10.1007/BF01631814 （德语）. 
  150. ^ Nakao K, Fujioka S. Thymidine kinase activity in the human bone marrow from various blood diseases. Life Sci. April 1968, 7 (8): 395–9. PMID 5649653. doi:10.1016/0024-3205(68)90039-8. 
  151. ^ Wickramasinghe SN, Olsen I, Saunders JE. Thymidine kinase activity in human bone marrow cells. Scand J Haematol. September 1975, 15 (2): 139–44. PMID 1059244. doi:10.1111/j.1600-0609.1975.tb01065.x. 
  152. ^ Gordon HL, Bardos TJ, Chmielewicz ZF, Ambrus JL. Comparative study of the thymidine kinase and thymidylate kinase activities and of the feedbach inhibition of thymidine kinase in normal and neoplastic human tissue. Cancer Res. October 1968, 28 (10): 2068–77. PMID 5696936. 
  153. ^ Stafford MA, Jones OW. The presence of "fetal" thymidine kinase in human tumors. Biochim. Biophys. Acta. August 1972, 277 (2): 439–42. PMID 4672678. 
  154. ^ Maehara Y, Nakamura H, Nakane Y; et al. Activities of various enzymes of pyrimidine nucleotide and DNA syntheses in normal and neoplastic human tissues. Gann. April 1982, 73 (2): 289–98. PMID 6288502. 
  155. ^ Persson L, Gronowitz SJ, Källander CF. Thymidine kinase in extracts of human brain tumours. Acta Neurochir (Wien). 1986, 80 (3–4): 123–7. PMID 3012969. doi:10.1007/BF01812286. 
  156. ^ Filanovskaia LI, Togo AV, Shcherbakova EG, Blinov MN. [Thymidine kinase activity in leukocytes from patients with chronic myeloid leukemia at various periods in the disease] [Thymidine kinase activity in leukocytes from patients with chronic myeloid leukemia at various periods in the disease]. Vopr. Med. Khim. 1994, 40 (1): 29–32. PMID 8122406 （俄语）. 
  157. ^ Lipkin M. Proliferation and differentiation of normal and neoplastic cells in the colon of man. Cancer. July 1971, 28 (1): 38–40. PMID 5110642. doi:10.1002/1097-0142(197107)28:1<38::AID-CNCR2820280108>3.0.CO;2-W. 
  158. ^ Lipkin M, Deschner E, Troncale F. Cell differentiation and the development of colonic neoplasms. CA Cancer J Clin. 1970, 20 (6): 386–90 [2012-03-13]. PMID 4992499. doi:10.3322/canjclin.20.6.386. （原始内容存档于2016-03-04）. 
  159. ^ Weber G, Lui MS, Takeda E, Denton JE. Enzymology of human colon tumors. Life Sci. September 1980, 27 (9): 793–9. PMID 7412505. doi:10.1016/0024-3205(80)90333-1. 
  160. ^ Sagara T, Tsukada K, Iwama T, Mishima Y, Sakamoto S, Okamoto R. [Thymidine kinase isozymes in human colon polyps] [Thymidine kinase isozymes in human colon polyps]. Nippon Gan Chiryo Gakkai Shi. August 1985, 20 (7): 1312–6. PMID 4078430 （日语）. 
  161. ^ Sakamoto S, Sagara T, Iwama T, Kawasaki T, Okamoto R. Increased activities of thymidine kinase isozymes in human colon polyp and carcinoma. Carcinogenesis. June 1985, 6 (6): 917–9. PMID 4006080. doi:10.1093/carcin/6.6.917. 
  162. ^ Sakamoto S, Okamoto R. Thymidine kinase activity in familial adenomatous polyposis. Tohoku J. Exp. Med. October 1992, 168 (2): 291–301. PMID 1339104. doi:10.1620/tjem.168.291. （原始内容存档于2012-12-19）. 
  163. ^ Galloux H, Javre JL, Guerin D, Sampérez S, Jouan P. [Prognostic value of fetal thymidine kinase measurements in breast cancer] [Prognostic value of fetal thymidine kinase measurements in breast cancer]. C. R. Acad. Sci. III, Sci. Vie. 1988, 306 (3): 89–92. PMID 3126994 （法语）. 
  164. ^ O'Neill KL, Hoper M, Odling-Smee GW. Can thymidine kinase levels in breast tumors predict disease recurrence?. J. Natl. Cancer Inst. December 1992, 84 (23): 1825–8. PMID 1433372. doi:10.1093/jnci/84.23.1825. 
  165. ^ O'Neill KL, McKelvey VJ, Hoper M; et al. Breast tumour thymidine kinase levels and disease recurrence. Med Lab Sci. December 1992, 49 (4): 244–7. PMID 1339926. 
  166. ^ Romain S, Javre JL, Samperez S; et al. [Prognostic value of thymidine kinase in cancer of the breast] [Prognostic value of thymidine kinase in cancer of the breast]. Bull Cancer. 1990, 77 (10): 973–83. PMID 2249017 （法语）. 
  167. ^ Romain S, Chinot O, Guirou O, Soullière M, Martin PM. Biological heterogeneity of ER-positive breast cancers in the post-menopausal population. Int. J. Cancer. October 1994, 59 (1): 17–9. PMID 7927897. doi:10.1002/ijc.2910590105. 
  168. ^ Sakamoto S, Iwama T, Ebuchi M; et al. Increased activities of thymidine kinase isozymes in human mammary tumours. Br J Surg. April 1986, 73 (4): 272–3. PMID 3697655. doi:10.1002/bjs.1800730409. 
  169. ^ Greengard O, Head JF, Goldberg SL, Kirschner PA. Enzyme pathology and the histologic categorization of human lung tumors: the continuum of quantitative biochemical indices of neoplasticity. Cancer. February 1982, 49 (3): 460–7. PMID 6277448. doi:10.1002/1097-0142(19820201)49:3<460::AID-CNCR2820490312>3.0.CO;2-Y. 
  170. ^ Greengard O, Head JF, Goldberg SL, Kirschner PA. Biochemical measure of the volume doubling time of human pulmonary neoplasms. Cancer. April 1985, 55 (7): 1530–5. PMID 2983858. doi:10.1002/1097-0142(19850401)55:7<1530::AID-CNCR2820550720>3.0.CO;2-V. 
  171. ^ Yusa T, Tamiya N, Yamaguchi Y; et al. [A study of thymidine kinase activity in lung cancer tissue] [A study of thymidine kinase activity in lung cancer tissue]. Nihon Kyobu Shikkan Gakkai Zasshi. March 1994, 32 (3): 211–5. PMID 8189640 （日语）. 
  172. ^ Konishi T, Miyama T, Sakamoto S; et al. Activities of thymidylate synthetase and thymidine kinase in gastric cancer. Surg Oncol. June 1992, 1 (3): 215–21. PMID 1341254. doi:10.1016/0960-7404(92)90067-U. 
  173. ^ Look KY, Moore DH, Sutton GP, Prajda N, Abonyi M, Weber G. Increased thymidine kinase and thymidylate synthase activities in human epithelial ovarian carcinoma. Anticancer Res. 1997, 17 (4A): 2353–6. PMID 9252646. 
  174. ^ Greengard O, Head JF, Chahinian AP, Goldberg SL. Enzyme pathology of human mesotheliomas. J. Natl. Cancer Inst. April 1987, 78 (4): 617–22. PMID 2882044. 
  175. ^ Borovanský J, Stríbrná J, Elleder M, Netíková I. Thymidine kinase in malignant melanoma. Melanoma Res. October 1994, 4 (5): 275–9. PMID 7858409. doi:10.1097/00008390-199410000-00001. 
  176. ^ Sakamoto S, Murakami S, Sugawara M, Mishima Y, Okamoto R. Increased activities of thymidylate synthetase and thymidine kinase in human thyroid tumors. Thyroid. 1991, 1 (4): 347–51. PMID 1841732. doi:10.1089/thy.1991.1.347. 
  177. ^ Pikner R, Ludvíkova M, Ryska A; et al. TPS, thymidine kinase, VEGF and endostatin in cytosol of thyroid tissue samples. Anticancer Res. 2005, 25 (3A): 1517–21. PMID 16033053. 
  178. ^ Wilms K, Wilmanns W. [Effects of dauno-rubidomycin and adriamycin on enzymes of DNA synthesis in leukocytes in vivo and in culture] [Effects of dauno-rubidomycin and adriamycin on enzymes of DNA synthesis in leukocytes in vivo and in culture]. Klin. Wochenschr. September 1972, 50 (18): 866–70. PMID 4507472. doi:10.1007/BF01488943 （德语）. 
  179. ^ Wilmanns W, Wilms K. DNA synthesis in normal and leucemic cells as related to therapy with cytotoxic drugs. Enzyme. 1972, 13 (1): 90–109. PMID 4507104. 
  180. ^ Zhang HJ, Kennedy BJ, Kiang DT. Thymidine kinase as a predictor of response to chemotherapy in advanced breast cancer. Breast Cancer Res. Treat. 1984, 4 (3): 221–5. PMID 6487823. doi:10.1007/BF01806488. 
  181. ^ Kuroiwa N, Nakayama M, Fukuda T; et al. Specific recognition of cytosolic thymidine kinase in the human lung tumor by monoclonal antibodies raised against recombinant human thymidine kinase. J. Immunol. Methods. July 2001, 253 (1–2): 1–11 [2012-03-13]. PMID 11384664. doi:10.1016/S0022-1759(01)00368-4. （原始内容存档于2018-06-14）. 
  182. ^ 182.0 182.1 He Q, Mao Y, Wu J; et al. Cytosolic thymidine kinase is a specific histopathologic tumour marker for breast carcinomas. Int. J. Oncol. October 2004, 25 (4): 945–53. PMID 15375544. 
  183. ^ Mao Y, Wu J, Wang N; et al. A comparative study: immunohistochemical detection of cytosolic thymidine kinase and proliferating cell nuclear antigen in breast cancer. Cancer Invest. 2002, 20 (7–8): 922–31. PMID 12449723. doi:10.1081/CNV-120005905. 
  184. ^ Mao Y, Wu J, Skog S; et al. Expression of cell proliferating genes in patients with non-small cell lung cancer by immunohistochemistry and cDNA profiling. Oncol. Rep. May 2005, 13 (5): 837–46. PMID 15809747. 
  185. ^ Wu J, Mao Y, He L; et al. A new cell proliferating marker: cytosolic thymidine kinase as compared to proliferating cell nuclear antigen in patients with colorectal carcinoma. Anticancer Res. 2000, 20 (6C): 4815–20. PMID 11205225. 
  186. ^ Li HX, Lei DS, Wang XQ, Skog S, He Q. Serum thymidine kinase 1 is a prognostic and monitoring factor in patients with non-small cell lung cancer. Oncol. Rep. January 2005, 13 (1): 145–9. PMID 15583816. 
  187. ^ Stephan Kruck, Joerg Hennenlotter, Ulrich Vogel, David Schilling, Georgios Gakis, Joachim Hevler, Ursula Kuehs, Arnulf Stenzl, Christian Schwentner. Exposed proliferation antigen 210 (XPA-210) in renal cell carcinoma (RCC) and oncocytoma: clinical utility and biological implications. BJU international. 2012-2, 109 (4): 634–638 [2019-05-26]. ISSN 1464-410X. PMID 21711439. doi:10.1111/j.1464-410X.2011.10392.x. （原始内容存档于2016-06-07）. 

外部链接

检索自“https://zh.wikipedia.org/w/index.php?title=胸苷激酶&oldid=79726525”